Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Real-world insights into bladder cancer molecular profiling

Alan Tan, MD, Vanderbilt Ingram Cancer Center, Nashville, TN, presents findings on the utility of urinary tumor DNA (utDNA) for real-world bladder cancer monitoring. Similar to plasma circulating tumor (ctDNA), utDNA offers a non-invasive approach for genomic profiling and treatment monitoring, particularly for patients undergoing neoadjuvant chemotherapy or bladder-preserving strategies. By incorporating methylation and whole transcriptome analysis, this evolving assay aims to provide a more comprehensive view or tumor heterogeneity and actionable mutations. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.